Log in to save to my catalogue

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_gup_ub_gu_se_259619

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

About this item

Full title

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2017-09, Vol.377 (12), p.1119-1131

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The 150-mg dose, but not the 50-mg or 300-mg dose, led to a lower incidence of recurrent cardiovascular events.

Alternative Titles

Full title

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_swepub_primary_oai_gup_ub_gu_se_259619

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_gup_ub_gu_se_259619

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1707914

How to access this item